Untitled Letters 2017
These letters are supplied by the CDER Freedom of Information Office and only covers Office of Prescription Drug Promotion's untitled letters. The agency may have redacted or edited some of the letters to remove confidential information.
Office of Prescription Drug Promotion
|
Company/Individual |
Product/Issue |
Issue Date |
|---|---|---|
|
University of California Los Angeles (UCLA)
|
Gallium 68 (68GA-PSMA) (Prostate Cancer Imaging webpage and brochure) |
12/28/2017 |
|
Orexigen Therapeutics, Inc. |
NDA 200063 CONTRAVE (naltrexone HCl and bupropion HCl) Extended-Release Tablets |
5/18/2017 |